A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: Who might be possible candidates for adjuvant treatment?

Breast Cancer Research and Treatment

Volumn 119, Issue 3, 2010, Pages 653-661

  Park, Yeon Hee ^a   Kim, Seung Tae ^a   Cho, Eun Yoon ^a   Choi, Yoon La ^a   Ok, Oh Nam ^a   Baek, Hae Jin ^a   Lee, Jeong Eon ^a   Nam, Seok Jin ^a   Yang, Jung Hyun ^a   Park, Won ^a   Choi, Doo Ho ^a   Huh, Seung Jae ^a   Ahn, Jin Seok ^a   Im, Young Hyuck ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

1 cm Invasive breast cancer; Adjuvant treatment; HER 2; Triple negative breast cancer (TNBC)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER INVASION; CANCER RECURRENCE; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; HIGH RISK POPULATION; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK; RISK FACTORS;

EID: 74849127904     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0665-x     Document Type: Article

References (62)

1. BA Miller EJ Feuer BF Hankey 1993 Recent incidence trends for breast cancer in women and the relevance of early detection: an update CA Cancer J Clin 43 27 41 10.3322/canjclin.43.1.27 8422603 1:STN:280:DyaK3s7jslWjuw%3D%3D
2. A Jemal LX Clegg E Ward, et al. 2004 Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival Cancer 101 3 27 10.1002/cncr.20288 15221985 (Pubitemid 38812419)
3. M Schootman D Jeffe A Reschke, et al. 2004 The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States Breast Cancer Res Treat 85 219 222 10.1023/B:BREA.0000025410.41220.67 15111759 (Pubitemid 38987255)
4. PP Rosen S Groshen DW Kinne, et al. 1993 Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up J Clin Oncol 11 2090 2100 8229123 1:STN:280: DyaK2c%2FksFyisA%3D%3D
5. H Joensuu L Pylkkänen S Toikkanen 1999 Late mortality from pT1N0M0 breast carcinoma Cancer 85 2183 2189 10.1002/(SICI)1097-0142(19990515)85: 10<2183::AID-CNCR12>3.0.CO;2-K 10326696 1:STN:280:DyaK1M3ls1Khug%3D%3D (Pubitemid 29215557)
6. YY Chen SJ Schnitt 1998 Prognostic factors for patients with breast cancers 1 cm and smaller Breast Cancer Res Treat 51 209 225 10.1023/A: 1006130911110 10068080 1:STN:280:DyaK1M7msFCnuw%3D%3D (Pubitemid 29054555)
7. SP Leitner AS Swern D Weinberger, et al. 1995 Predictors of recurrence of patients with small (one centimeter or less) localized breast cancer (T1a, bN0M0) Cancer 76 2266 2274 10.1002/1097-0142(19951201)76:11<2266::AID- CNCR2820761114>3.0.CO;2-T 8635031 1:STN:280:DyaK283itlarsg%3D%3D
8. CA Quiet DJ Ferguson RR Weichselbaum, et al. 1995 Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up J Clin Oncol 13 1144 1151 7738620 1:STN:280:DyaK2M3ls12gtw%3D%3D
9. SK Chia CH Speers CJ Bryce, et al. 2004 Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies J Clin Oncol 22 1630 1637 10.1200/JCO.2004.09.070 15117985 (Pubitemid 41079801)
10. M Martin T Pienkowski J Mackey, et al. 2005 Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302 2313 10.1056/NEJMoa043681 15930421 1:CAS:528:DC%2BD2MXksl2lt7c%3D (Pubitemid 40740554)
11. IC Henderson DA Berry GD Demetri, et al. 2003 Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976 983 10.1200/JCO.2003.02.063 12637460 1:CAS:528:DC%2BD2cXpsVGqs7c%3D (Pubitemid 46594124)
12. P Eifel JA Axelson J Costa, et al. 2001 National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer J Natl Cancer Inst 93 978 989 10.1093/jnci/93.13.978
13. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology, Version 1.2009, Breast Cancer. http://www.nccn.org/professinals/ physician-gls/PDF/breast.pdf
14. A Goldhirsch WC Wood RD Gelber, et al. 2007 10th St. Gallen conference: progress, promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 7 1133 1144 10.1093/annonc/mdm271 17675394 1:STN:280:DC%2BD2svlvVSkuw%3D%3D (Pubitemid 47244357)
15. AK Lee M Loda G Mackarem, et al. 1997 Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a, bN0M0): clinicopathologic features and outcome Cancer 79 761 771 10.1002/(SICI)1097-0142(19970215)79:4<761:: AID-CNCR13>3.0.CO;2-Y 9024714 1:STN:280:DyaK2s7nslWlsA%3D%3D (Pubitemid 27076342)
16. GB Mann ER Port C Rizza, et al. 1999 Six-year follow-up of patients with microinvasive, T1a, and T1b breast carcinoma Ann Surg Oncol 6 591 598 10.1007/s10434-999-0591-5 10493629 1:STN:280:DyaK1MvitFeksA%3D%3D (Pubitemid 29428800)
17. DJ Slamon W Godolphin LA Jones, et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712 10.1126/science.2470152 2470152 1:STN:280:DyaL1M3kt1Wntg%3D%3D
18. DJ Slamon GM Clark SG Wong, et al. 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 10.1126/science.3798106 3798106 1:CAS:528:DyaL2sXhtVSht7s%3D
19. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2 N Engl J Med 344 783 792 10.1056/NEJM200103153441101 11248153 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
20. M Colleoni N Rotmensz G Peruzzotti, et al. 2004 Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies Ann Oncol 15 1633 1639 10.1093/annonc/mdh434 15520064 1:STN:280:DC%2BD2crkslSksg%3D%3D (Pubitemid 39562603)
21. AN Mirza NQ Mirza G Vlastos, et al. 2002 Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years Ann Surg 235 10 26 10.1097/00000658-200201000- 00003 11753038 (Pubitemid 34062395)
22. S Chia B Norris C Speers, et al. 2008 Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers J Clin Oncol 26 5697 5704 10.1200/JCO.2007.15.8659 19001334 1:CAS:528:DC%2BD1MXotFemsw%3D%3D
23. H Joensuu J Isola M Lundin, et al. 2003 Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study Clin Cancer Res 9 923 930 12631589 1:CAS:528:DC%2BD3sXhvFKiuro%3D
24. YH Choi JH Ahn SB Kim, et al. 2009 Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis Ann Oncol 20 1337 1343 10.1093/annonc/mdp003 19221151 1:STN:280:DC%2BD1Mrjtlansg%3D%3D
25. MJ Piccart-Gebhart M Procter B Leyland-Jones, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 10.1056/NEJMoa052306 16236737 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
26. H Joensuu PL Kellokumpu-Lehtinen P Bono, et al. 2006 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 809 820 10.1056/NEJMoa053028 16495393 1:CAS:528:DC%2BD28Xhsl2gsrY%3D (Pubitemid 43290919)
27. EH Romond EA Perez J Bryant, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 10.1056/NEJMoa052122 16236738 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
28. D Slamon W Eiermann N Robert, et al. 2005 Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study Breast Cancer Res Treat 94 suppl 1 S5
29. JE Uhm YH Park SY Yi, et al. 2009 Treatment outcomes and clnicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy Int J Cancer 124 1457 1462 10.1002/ijc.24090 19065658 1:CAS:528:DC%2BD1MXisFGgsLg%3D
30. JW Chia P Ang H See, et al. 2007 Triple-negative metastatic/recurrent breast cancer: treatment with paclitaxel/carboplatin combination chetmotherapy (abstract 1086) J Clin Oncol 26 suppl 15 43s
31. JE Garber A Richardson LN Harris, et al. 2006 Neo-adjuvant cisplatin in triple-negative breast cancer (abstract 3074) Breast Cancer Res Treat 100 S149 10.1007/s10549-006-9235-7 (Pubitemid 44631916)
32. TO Nielsen FD Hsu K Jensen, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 10.1158/1078-0432.CCR-04-0220 15328174 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
33. KA Hoadley VJ Weigman C Fan, et al. 2007 EGFR associated expression profiles vary with breast cancer subtype BMC Genomics 8 258 10.1186/1471-2164-8- 258 17663798 1:CAS:528:DC%2BD2sXhtValsbzK (Pubitemid 47559211)
34. K Miller M Wang J Gralow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 10.1056/NEJMoa072113 18160686 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D
35. J O'Shaughnessy C Osborne M Yoffe, et al. 2009 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial J Clin Oncol 27 suppl 2 793s36
36. J Gronwald T Byrski T Huzarski, et al. 2009 Neoadjuvant therapy with cisplatin in BRCA-positive breast cancer patients J Clin Oncol 27 suppl 1 7s
37. LM McShane 2005 Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 9067 9072 10.1200/JCO.2004.01.0454 16172462 (Pubitemid 46260161)
38. LM McShane DG Altman W Sauerbrei, et al. 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 229 235 10.1007/s10549-006-9242-8 16932852 (Pubitemid 44631925)
39. S Paik S Shak G Tang, et al. 2004 A multigene assay to predict recurrence of tamoxifen treted, node-negative breast cancer N Engl J Med 351 2817 2826 10.1056/NEJMoa041588 15591335 1:CAS:528:DC%2BD2MXhslymsw%3D%3D (Pubitemid 40051905)
40. S Paik 2007 Development and clnical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated wtih tamoxifen Oncologist 12 615 631 10.1634/theoncologist.12-6-631 1:CAS:528: DC%2BD2sXosF2gs7o%3D (Pubitemid 47036199)
41. MJ van de Vijver YD He LJ van't Veer, et al. 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 1999 2009 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
42. J Bogaerts F Cardoso M Buyse, et al. 2006 TRANSBIG Consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial Nat Clin Pract Oncol 3 540 551 10.1038/ncponc0591 17019432 1:CAS:528:DC%2BD28XhtFKqtbzE (Pubitemid 44781724)
43. CL Carter C Allen DE Henson 1989 Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases Cancer 63 181 187 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H 2910416 1:STN:280:DyaL1M%2FovFCqug%3D%3D (Pubitemid 19032001)
44. IA Olivotto JS Jackson D Mates, et al. 1998 Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis Cancer 83 948 955 10.1002/(SICI)1097-0142(19980901)83:5<948::AID- CNCR21>3.0.CO;2-U 9731899 1:STN:280:DyaK1cvgtVKhtw%3D%3D (Pubitemid 28401929)
45. DC Malbenco LK Welss KS Pawllsh, et al. 1999 Axillary lymph node metastases associated with small invasive breast carcinomas Cancer 85 1530 1536 10.1002/(SICI)1097-0142(19990401)85:7<1530::AID-CNCR14>3.0.CO;2-U (Pubitemid 29152825)
46. DE Rivadeneira RM Simmons PJ Christos, et al. 2000 Predictive factors associated with lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients J Am Coll Surg 191 1 6 10.1016/S1072-7515(00)00310-0 10898177 1:STN:280:DC%2BD3czlsVGnsA%3D%3D (Pubitemid 30439553)
47. S Laura NJ Coombs O Ung, et al. 2006 Tumour size as a predictor of axillary node metastases in patients with breast cancer ANZ J Surg 76 1002 1006 10.1111/j.1445-2197.2006.03918.x 17054550 (Pubitemid 44581490)
48. NG Coburn E Clarke-Pearson MA Chung, et al. 2006 A novel approach to T classification in tumor-node-metastasis staging of breast cancer Am J Surg 192 434 438 10.1016/j.amjsurg.2006.06.032 16978944 (Pubitemid 44344209)
49. NJ Coombs J Boyages 2005 Multifocal and multicentric breast cancer: does each focus matter? J Clin Oncol 23 7497 7502 10.1200/JCO.2005.02.1147 16234516 (Pubitemid 46304480)
50. EA Rakha ME El-Sayed AHS Lee, et al. 2008 Prognostic significance of Nottingham histologic grade in invasive breast carcinoma J Clin Oncol 26 3153 3158 10.1200/JCO.2007.15.5986 18490649
51. B Van Calster I Vanden Bempt M Drijkoningen, et al. 2009 Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive Breast Cancer Res Treat 113 181 187 10.1007/s10549-008-9914-7 18264760 1:CAS:528:DC%2BD1cXhsFWrs7nP
52. C Marchiò R Natrajan KK Shiu, et al. 2008 The genomic profile of HER2-amplified breast cancers: the influence of ER status J Pathol 216 399 407 10.1002/path.2423 18810758
53. A Prat J Baselga 2008 The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 Nat Clin Pract Oncol 5 531 542 10.1038/ncponc1179 18607391 1:CAS:528:DC%2BD1cXhtVGgt7fE
54. Y Kun LC How TP Hoon, et al. 2003 Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor Hum Mol Genet 12 3245 3258 10.1093/hmg/ddg347 14570715 1:CAS:528:DC%2BD3sXpsl2mt7k%3D (Pubitemid 37541070)
55. MC Cheang SK Chia D Voduc, et al. 2009 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 736 750 10.1093/jnci/djp082 19436038 1:CAS:528:DC%2BD1MXmtlyit74%3D
56. M Untch RD Gelber C Jackisch, et al. 2008 Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial Ann Oncol 19 1090 1096 10.1093/annonc/mdn005 18296421 1:STN:280:DC%2BD1czktlSlsA%3D%3D (Pubitemid 351796334)
57. R Dent M Trudeau KI Pritchard, et al. 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429 4434 10.1158/1078-0432.CCR-06-3045 17671126 (Pubitemid 47219710)
58. WD Foulkes JS Bruder JM Stefansson, et al. 2004 The prognostic implication of the basal-like (cycle E high/p27low/p53+/glomeruloid- microvascular proliferation+) phenotype of BRCA1-related breast cancer Cancer Res 64 830 835 10.1158/0008-5472.CAN-03-2970 14871808 1:CAS:528: DC%2BD2cXhtFCgtLo%3D (Pubitemid 38176880)
59. WD Foulkes K Metcalfe W Hanna, et al. 2003 Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA-1 related breast carcinoma Cancer 98 1569 1577 10.1002/cncr.11688 14534871 (Pubitemid 37238611)
60. YS Jung SS Ko HJ Youn, et al. 2008 Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996-2006) using nationwide breast cancer registration on-line program: biannual update J Surg Oncol 98 318 323 10.1002/jso.21110
61. KY Yoo D Kang SK Park, et al. 2002 Epidemiology of breast cancer in Korea: occurrence, high-risk groups, and prevention J Korean Med Sci 17 1 6 11850580
62. H Chang SY Rha HC Jeung, et al. 2009 Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients Ann Oncol 20 272 277 10.1093/annonc/mdn624 18836089 1:STN:280:DC%2BD1M7jtlWlsA%3D%3D